Beta-1,3-galactosyltransferase homologs

Abstract

The present invention relates to polynucleotide and polypeptide molecules for znssp2, a novel member of the galactosyltransferase family. The polypeptides, and polynucleotides encoding them, are cell-cell interaction and glycoprotein synthesis modulating and may be used for delivery and therapeutics. The present invention also includes antibodies to the znssp2 polypeptides.

What is claimed is:  
     
         1 . An isolated polypeptide comprising residues 148 to 397 of SEQ ID NO:2.  
     
     
         2 . The isolated polypeptide according to  claim 1  wherein the polypeptide comprises residues 19 to 397 of SEQ ID NO:2.  
     
     
         3 . The isolated polypeptide according to  claim 2  wherein the polypeptide comprises residues 1 to 397 of SEQ ID NO:2.  
     
     
         4 . An isolated polypeptide selected from the group consisting of: 
 a) a polypeptide comprising residues 1 to 18 of SEQ ID NO:2;    b) a polypeptide comprising residues 19 to 147 of SEQ ID NO:2;    c) a polypeptide comprising residues 148 to 397 of SEQ ID NO:2;    d) a polypeptide comprising residues 19 to 397 of SEQ ID NO:2; and    e) a polypeptide comprising residues 1 to 397 of SEQ ID NO:2.    
     
     
         5 . An isolated polynucleotide encoding a polypeptide wherein the polypeptide comprises residues 148 to 397 of SEQ ID NO:2.  
     
     
         6 . The isolated polynucleotide according to  claim 5 , wherein the polypeptide molecule comprises residues 19 to 397 of SEQ ID NO:2.  
     
     
         7 . The isolated polynucleotide according to  claim 5 , wherein the polypeptide molecule comprises residues 1 to 397 of SEQ ID NO:2.  
     
     
         8 . An isolated polynucleotide encoding a polypeptide molecule wherein the polypeptide is selected from the group consisting of: 
 a) a polypeptide comprising residues 1 to 18 of SEQ ID NO:2;    b) a polypeptide comprising residues 19 to 147 of SEQ ID NO:2;    c) a polypeptide comprising residues 148 to 397 of SEQ ID NO:2;    d) a polypeptide comprising residues 19 to 397 of SEQ ID NO:2; and    e) a polypeptide comprising residues 1 to 397 of SEQ ID NO:2.    
     
     
         9 . An expression vector comprising the following operably linked elements: 
 a transcription promoter;    a DNA segment wherein the DNA segment is a polynucleotide encoding the polypeptide of  claim 1;  and    a transcription terminator.    
     
     
         10 . The expression vector according to  claim 9  wherein the DNA segment contains an affinity tag.  
     
     
         11 . A cultured cell into which has been introduced an expression vector according to  claim 9 , wherein said cell expresses the polypeptide encoded by the DNA segment.  
     
     
         12 . A method of producing a polypeptide comprising culturing a cell according to  claim 11 , whereby said cell expresses the polypeptide encoded by the DNA segment; and recovering the polypeptide.  
     
     
         13 . A method of producing an antibody comprising the following steps in order: 
 inoculating an animal with a polypeptide selected from the group consisting of: 
 a) polypeptide comprising residues 1 to 18 of SEQ ID NO:2;  
 b) a polypeptide comprising residues 19 to 147 of SEQ ID NO:2;  
 c) a polypeptide comprising residues 148 to 397 of SEQ ID NO:2;  
 d) a polypeptide comprising residues 19 to 397 of SEQ ID NO:2; and  
 e) a polypeptide comprising residues 1 to 397 of SEQ ID NO:2.  
   wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.    
     
     
         14 . An antibody produced by the method of  claim 13 , which binds to a residues 1 to 397 of SEQ ID NO:2.  
     
     
         15 . The antibody of  claim 14 , wherein the antibody is a monoclonal antibody.  
     
     
         16 . An antibody which specifically binds to a polypeptide of  claim 3 .  
     
     
         17 . A method of producing an antibody comprising the following steps in order: 
 inoculating an animal with an epitope bearing portion of a polypeptide wherein the epitope bearing portion is selected from the group consisting of: 
 a) a polypeptide consisting of residues 1 to 6 of SEQ ID NO:2;  
 b) a polypeptide consisting of residues 26 to 54 of SEQ ID NO:2;  
 c) a polypeptide consisting of residues 82 to 94 of SEQ ID NO:2;  
 d) a polypeptide consisting of residues 110 to 117 of SEQ ID NO:2;  
 e) a polypeptide consisting of residues 110 to 127 of SEQ ID NO:2;  
 f) a polypeptide consisting of residues 122 to 127 of SEQ ID NO:2;  
 g) a polypeptide consisting of residues 122 to 136 of SEQ ID NO:2;  
 h) a polypeptide consisting of residues 131 to 136 of SEQ ID NO:2;  
 i) a polypeptide consisting of residues 131 to 146 of SEQ ID NO:2;  
 j) a polypeptide consisting of residues 139 to 146 of SEQ ID NO:2;  
 k) a polypeptide consisting of residues 154 to 177 of SEQ ID NO:2;  
 l) a polypeptide consisting of residues 187 to 197 of SEQ ID NO:2;  
 m) a polypeptide consisting of residues 187 to 207 of SEQ ID NO:2;  
 n) a polypeptide consisting of residues 202 to 207 of SEQ ID NO:2;  
 o) a polypeptide consisting of residues 282 to 289 of SEQ ID NO:2;  
 p) a polypeptide consisting of residues 282 to 301 of SEQ ID NO:2;  
 q) a polypeptide consisting of residues 295 to 301 of SEQ ID NO:2;  
 r) a polypeptide consisting of residues 358 to 365 of SEQ ID NO:2;  
 s) a polypeptide consisting of residues 358 to 397 of SEQ ID NO:2; and  
 t) a polypeptide consisting of residues 387 to 397 of SEQ ID NO:2;  
   wherein the polypeptide elicits an immune response in the animal to produce the antibody; and isolating the antibody from the animal.    
     
     
         18 . An antibody produced by the method of  claim 17 , which binds to a residues 1 to 397 of SEQ ID NO:2.  
     
     
         19 . The antibody of  claim 18 , wherein the antibody is a monoclonal antibody.  
     
     
         20 . A method for modulating cell-cell interactions by combining the polypeptide according to  claim 1 , with cells in vivo and in vitro.  
     
     
         21 . A method for modulating cell-cell interactions according to  claim 20 , whereby the cells are derived from tissues selected from the group consisting of: 
 a) tissues from pancreas;    b) tissues from colon;    c) tissues from small intestine;    d) tissues from bladder;    e) tissues from prostate;    f) tissues from myometrium; and    g) tissues from breast.    
     
     
         22 . A method for modulating glycoprotein and glycolipid biosynthesis by combining the polypeptide according to  claim 1 , with cells in vivo and in vitro.  
     
     
         23 . A method for modulating cell-cell interactions according to  claim 22 , whereby the cells are derived from tissues selected from the group consisting of: 
 a) tissues from pancreas;    b) tissues from colon;    c) tissues from small intestine;    d) tissues from bladder;    e) tissues from prostate;    f) tissues from myometrium; and    g) tissues from breast.    
     
     
         24 . A method of detecting a molecule which binds to a polypeptide comprising contacting the polypeptide with a test sample containing the molecule wherein the polypeptide comprises residues 148 to 397 of SEQ ID NO:2 and whereby the molecule binds the polypeptide.